In the world of finance and technology, a new debate has emerged, with some experts warning of a potential 'debt bomb' crisis due to the off-balance-sheet financing practices of major tech companies. The concern is that these companies, such as Meta, Oracle, xAI, and CoreWeave, are raising billions to build datacenters without recognizing these long-term debt obligations on their balance sheets. This has led to comparisons with the Enron scandal, which caused a historic market meltdown. However, I argue that this is a misunderstanding of the situation, and the risks are not as severe as they seem.
What makes this particularly fascinating is the historical context. In the 1980s and early 1990s, biotechnology companies like Centocor, Genentech, and Amgen were also engaging in off-balance-sheet financing to raise money for drug development. These partnerships, which held a minority interest in the entity but issued debt and took in investments, were common practice at the time. While some drugs failed in clinical testing, this did not cause a stock market panic, as the risks were spread. The public was largely unaware of these vehicles, and the accounting practices evolved over time.
In today's context, the risks are different. The disclosures required by companies doing off-balance-sheet financing are significant, and the scrutiny is intense. The investing public is smarter, and the risks are arguably more recoverable. The market need for datacenters is legitimate, and AI is not going away. According to Microsoft, only 17.8% of the world's working-age population currently uses generative AI, so we're still much closer to the beginning of adoption than the end. Some investments will fail, and some lenders will lose money, but that's exactly why these financing structures exist: to spread enormous capital requirements and risk among investors willing to take it.
One thing that immediately stands out is the difference between the risks of off-balance-sheet financing in the biotechnology industry and the risks of today's datacenters. In the 1990s, companies like Centocor were raising millions in partnerships that were developing products with a high probability of failure during clinical testing. Today, investors are financing land, buildings, electrical infrastructure, and computing equipment. A datacenter can disappoint financially, but it doesn't disappear because a clinical trial fails. This is why Jeff Bezos calls AI an 'industrial bubble' - industrial bubbles leave things behind, and this time, it's datacenters.
From my perspective, the concern about a debt bomb crisis is overblown. The obligations are disclosed, the assets are real, and demand for computing capacity remains strong. I see financial engineering, but I don't see a debt bomb. The risks are different, and the accounting practices have evolved. The public is smarter, and the scrutiny is intense. If we take a step back and think about it, the risks are spread, and the market need for datacenters is legitimate. So, I'm not losing sleep over big tech's off-balance-sheet debt.
